GB0016138D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0016138D0
GB0016138D0 GBGB0016138.0A GB0016138A GB0016138D0 GB 0016138 D0 GB0016138 D0 GB 0016138D0 GB 0016138 A GB0016138 A GB 0016138A GB 0016138 D0 GB0016138 D0 GB 0016138D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
mcp
eotaxin
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0016138.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0016138.0A priority Critical patent/GB0016138D0/en
Publication of GB0016138D0 publication Critical patent/GB0016138D0/en
Priority to PE2001000649A priority patent/PE20020125A1/es
Priority to ARP010103086A priority patent/AR046379A1/es
Priority to JP2002507891A priority patent/JP3920215B2/ja
Priority to NZ523195A priority patent/NZ523195A/en
Priority to IL15372101A priority patent/IL153721A0/xx
Priority to US10/312,022 priority patent/US20040047860A1/en
Priority to BR0112086-7A priority patent/BR0112086A/pt
Priority to KR1020027017405A priority patent/KR100603899B1/ko
Priority to ES01962800T priority patent/ES2322643T3/es
Priority to PL359854A priority patent/PL207133B1/pl
Priority to EP01962800A priority patent/EP1299421B1/en
Priority to AU8390301A priority patent/AU8390301A/xx
Priority to RU2003100512/13A priority patent/RU2314316C2/ru
Priority to DE60138102T priority patent/DE60138102D1/de
Priority to PT01962800T priority patent/PT1299421E/pt
Priority to PCT/EP2001/007468 priority patent/WO2002002640A2/en
Priority to HU0301477A priority patent/HUP0301477A3/hu
Priority to CZ20024256A priority patent/CZ20024256A3/cs
Priority to CA002412775A priority patent/CA2412775A1/en
Priority to AU2001283903A priority patent/AU2001283903B2/en
Priority to SK1812-2002A priority patent/SK18122002A3/sk
Priority to MXPA03000201A priority patent/MXPA03000201A/es
Priority to CNB018120652A priority patent/CN100486996C/zh
Priority to AT01962800T priority patent/ATE426616T1/de
Priority to NO20026063A priority patent/NO20026063L/no
Priority to EC2002004402A priority patent/ECSP024402A/es
Priority to ZA200300199A priority patent/ZA200300199B/en
Priority to JP2006314441A priority patent/JP2007054079A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0016138.0A 2000-06-30 2000-06-30 Organic compounds Ceased GB0016138D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB0016138.0A GB0016138D0 (en) 2000-06-30 2000-06-30 Organic compounds
PE2001000649A PE20020125A1 (es) 2000-06-30 2001-06-28 Moleculas de enlace a mcp-1
ARP010103086A AR046379A1 (es) 2000-06-30 2001-06-28 Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento
AT01962800T ATE426616T1 (de) 2000-06-30 2001-06-29 Antikírper gegen menschliches mcp-1
DE60138102T DE60138102D1 (de) 2000-06-30 2001-06-29 Antikörper gegen menschliches mcp-1
PCT/EP2001/007468 WO2002002640A2 (en) 2000-06-30 2001-06-29 Antibodies to human mcp-1
IL15372101A IL153721A0 (en) 2000-06-30 2001-06-29 Antibodies to human mcp-1
US10/312,022 US20040047860A1 (en) 2000-06-30 2001-06-29 Antibodies to human mcp-1
BR0112086-7A BR0112086A (pt) 2000-06-30 2001-06-29 Anticorpos para mcp-1 humano
KR1020027017405A KR100603899B1 (ko) 2000-06-30 2001-06-29 인간 ｍｃｐ-1에 대한 항체
ES01962800T ES2322643T3 (es) 2000-06-30 2001-06-29 Anticuerpos para mcp-1 humano.
PL359854A PL207133B1 (pl) 2000-06-30 2001-06-29 Cząsteczka wiążąca ludzkie monocytowe białko chemotaktyczne (MCP-1), konstrukt DNA, wektor ekspresyjny, kompozycja farmaceutyczna, sposób produkcji cząsteczki wiążącej MCP-1 oraz jej zastosowanie
EP01962800A EP1299421B1 (en) 2000-06-30 2001-06-29 Antibodies to human mcp-1
AU8390301A AU8390301A (en) 2000-06-30 2001-06-29 Antibodies to human MCP-1
RU2003100512/13A RU2314316C2 (ru) 2000-06-30 2001-06-29 Антитела к человеческому мср-1
JP2002507891A JP3920215B2 (ja) 2000-06-30 2001-06-29 ヒトｍｃｐ−１に対する抗体
PT01962800T PT1299421E (pt) 2000-06-30 2001-06-29 Anticorpos para a mcp-1 humana
NZ523195A NZ523195A (en) 2000-06-30 2001-06-29 Antibodies to human MCP-1
HU0301477A HUP0301477A3 (en) 2000-06-30 2001-06-29 Antibodies to human mcp-1 molecule
CZ20024256A CZ20024256A3 (cs) 2000-06-30 2001-06-29 Protilátky k humánnímu MCP-1
CA002412775A CA2412775A1 (en) 2000-06-30 2001-06-29 Antibodies to human mcp-1
AU2001283903A AU2001283903B2 (en) 2000-06-30 2001-06-29 Antibodies to human MCP-1
SK1812-2002A SK18122002A3 (sk) 2000-06-30 2001-06-29 Protilátky proti ľudskému MCP-1
MXPA03000201A MXPA03000201A (es) 2000-06-30 2001-06-29 Anticuerpos para mcp-1 humana.
CNB018120652A CN100486996C (zh) 2000-06-30 2001-06-29 人mcp-1的抗体
NO20026063A NO20026063L (no) 2000-06-30 2002-12-17 Antistoffer mot human MCP-1
EC2002004402A ECSP024402A (es) 2000-06-30 2002-12-24 Anticuerpos para mcp-1 humana
ZA200300199A ZA200300199B (en) 2000-06-30 2003-01-08 Antibodies to human MCP-1.
JP2006314441A JP2007054079A (ja) 2000-06-30 2006-11-21 ヒトｍｃｐ−１に対する抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0016138.0A GB0016138D0 (en) 2000-06-30 2000-06-30 Organic compounds

Publications (1)

Publication Number Publication Date
GB0016138D0 true GB0016138D0 (en) 2000-08-23

Family

ID=9894801

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0016138.0A Ceased GB0016138D0 (en) 2000-06-30 2000-06-30 Organic compounds

Country Status (27)

Country Link
US (1) US20040047860A1 (https=)
EP (1) EP1299421B1 (https=)
JP (2) JP3920215B2 (https=)
KR (1) KR100603899B1 (https=)
CN (1) CN100486996C (https=)
AR (1) AR046379A1 (https=)
AT (1) ATE426616T1 (https=)
AU (2) AU8390301A (https=)
BR (1) BR0112086A (https=)
CA (1) CA2412775A1 (https=)
CZ (1) CZ20024256A3 (https=)
DE (1) DE60138102D1 (https=)
EC (1) ECSP024402A (https=)
ES (1) ES2322643T3 (https=)
GB (1) GB0016138D0 (https=)
HU (1) HUP0301477A3 (https=)
IL (1) IL153721A0 (https=)
MX (1) MXPA03000201A (https=)
NO (1) NO20026063L (https=)
NZ (1) NZ523195A (https=)
PE (1) PE20020125A1 (https=)
PL (1) PL207133B1 (https=)
PT (1) PT1299421E (https=)
RU (1) RU2314316C2 (https=)
SK (1) SK18122002A3 (https=)
WO (1) WO2002002640A2 (https=)
ZA (1) ZA200300199B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
AR037456A1 (es) 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
NZ542784A (en) * 2002-08-19 2008-07-31 Astrazeneca Ab Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
WO2004024921A1 (ja) 2002-09-12 2004-03-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトｍｃｐ−１抗体及び該抗体フラグメント
WO2005044200A2 (en) * 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies
WO2005108431A1 (en) * 2004-05-04 2005-11-17 University Of Kentucky Research Foundation Methods and compositions for the treatment of ocular neovascularization
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
PE20061444A1 (es) * 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
EP2041568A4 (en) * 2006-06-15 2009-08-12 CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS
ES2434039T3 (es) * 2006-07-24 2013-12-13 Yeda Research And Development Co. Ltd. Composiciones farmacéuticas que comprenden ccl2 para su uso en el tratamiento de la inflamación
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CA2665808A1 (en) * 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis
WO2008077945A2 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
CN101827610A (zh) * 2007-06-29 2010-09-08 森托科尔奥索生物科技公司 抗mcp-1抗体、组合物、方法和用途
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
RU2547595C2 (ru) 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
EP2328930B1 (en) 2008-08-20 2014-12-24 Probiodrug AG Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
WO2010151416A1 (en) * 2009-06-25 2010-12-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
WO2013192596A2 (en) 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2
CA2958195A1 (en) * 2014-08-15 2016-02-18 PixarBio Corporation Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
CN105695495B (zh) * 2015-12-07 2020-02-18 中国石油大学(华东) 一种高活性人趋化因子的制备方法及用途
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
AU2020403913B2 (en) * 2019-12-18 2024-10-10 F. Hoffmann-La Roche Ag Bispecific anti-CCL2 antibodies
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CN119684454B (zh) * 2024-12-25 2025-09-12 武汉爱博泰克生物科技有限公司 针对人mcp-1蛋白的抗体、抗体对和试剂盒及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019552D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2572289A1 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
BR0112086A (pt) 2003-05-06
CZ20024256A3 (cs) 2003-04-16
ZA200300199B (en) 2003-11-13
PT1299421E (pt) 2009-06-26
US20040047860A1 (en) 2004-03-11
CA2412775A1 (en) 2002-01-10
HUP0301477A3 (en) 2005-11-28
PL207133B1 (pl) 2010-11-30
MXPA03000201A (es) 2003-05-27
IL153721A0 (en) 2003-07-06
AU2001283903B2 (en) 2005-06-02
NZ523195A (en) 2005-09-30
ECSP024402A (es) 2003-02-06
PL359854A1 (en) 2004-09-06
DE60138102D1 (de) 2009-05-07
RU2314316C2 (ru) 2008-01-10
JP3920215B2 (ja) 2007-05-30
CN100486996C (zh) 2009-05-13
EP1299421B1 (en) 2009-03-25
CN1443199A (zh) 2003-09-17
KR20030014272A (ko) 2003-02-15
WO2002002640A2 (en) 2002-01-10
NO20026063L (no) 2003-02-27
AR046379A1 (es) 2005-12-07
WO2002002640A3 (en) 2002-05-16
NO20026063D0 (no) 2002-12-17
HUP0301477A2 (hu) 2003-08-28
KR100603899B1 (ko) 2006-07-25
EP1299421A2 (en) 2003-04-09
ES2322643T3 (es) 2009-06-24
ATE426616T1 (de) 2009-04-15
AU8390301A (en) 2002-01-14
JP2007054079A (ja) 2007-03-08
JP2004502421A (ja) 2004-01-29
PE20020125A1 (es) 2002-03-12
SK18122002A3 (sk) 2003-06-03

Similar Documents

Publication Publication Date Title
GB0016138D0 (en) Organic compounds
GEP20074222B (en) Antibodies to cd40
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
DE602005022928D1 (de) Antikörper gegen gpnmb und ihre verwendungen
WO2005103081A3 (en) Human monoclonal antibodies against cd20
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2002072832A3 (en) Therapeutic binding molecules
CO5631451A2 (es) Anticuerpo especifico para cd22 humano y composicion farmaceutica derivada
SG151284A1 (en) Antibodies against ccr5 and uses thereof
WO2002072635A3 (en) Specific binding members
NZ595235A (en) Compositions and methods for increasing muscle growth
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
WO2003075855A3 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2003049704A3 (en) Antibodies to treat cancer
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
WO2004067564A3 (en) Compositions against cancer antigen liv-1 and uses thereof
WO2004053102A3 (en) Antibodies to treat cancer
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)